Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics (KYTX) to $31 from $27 and keeps an Overweight rating on the shares after the company announced interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of KYV-101 in generalized myasthenia gravis. KYV-101’s pivotal programs in MG and stiff person syndrome are “highly de-risked and remain unappreciated by investors,” the analyst argues.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data
- Kyverna Therapeutics Reports Positive Phase 2 Trial Results
- Kyverna Therapeutics announces data from Phase 2 from KYSA-6 clinical trial
- Kyverna Therapeutics Advances CAR T-Cell Therapy Study for Myasthenia Gravis
- Kyverna Therapeutics Advances with Promising CAR-T Therapy for Stiff Person Syndrome